Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy
Neurotransmitter receptors and neurotransmitter transporters were studied postmortem in the brains of 9 PSP patients by receptor autoradiography. Densities of dopamine uptake sites and neurotensin receptors were significantly reduced in striatum and substantia nigra consistent with a localization of these binding sites on degenerating dopaminergic nigrostriatal projection neurons. The densities of dopamine D1 receptors were unchanged. Dopamine D2 receptors were unaltered when labeled by [125I]-Iodosulpride or [3H]-CV 205 502, but appeared to be significantly reduced when labeled by [3H]-spiperone. Levels of D2 mRNA were comparable to control levels, suggesting that only subtypes of Dopamine D2-like receptors may be affected in PSP. Serotonin (5-HT) uptake sites and 5-HT receptors were not altered. The density of muscarinic receptors was reduced in striatum, possibly related to a degeneration of cholinergic striatal inter-neurons, but increased in internal globus pallidus. GABAA/BZ receptor binding sites were significantly reduced in both segments of globus pallidus, probably as a consequence of severe degeneration of intrinsic pallidal neurons in PSP. Binding of substance P in striatum tended to be decreased but failed to reach statistical significance. Compared to Parkinson’s disease, the densities of more neurotransmitter receptors were altered in PSP. With the exception of increased muscarinic receptor binding sites in medial globus pallidus, the alterations seen in PSP seem to reflect cell loss rather than functional changes.
KeywordsMuscarinic Receptor Globus Pallidus Progressive Supranuclear Palsy Neurotransmitter Receptor Internal Globus Pallidus
Unable to display preview. Download preview PDF.
- Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C., Hauw J-J, Baron J-C, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergman KJ (eds) Advances in neurology, vol 45. Raven Press, New York.Google Scholar
- D’Amato RJ, Largent BL, Snowman AM, Snyder SH (1987) Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther 242: 364–371.Google Scholar
- Golbe LI, Davies PH (1988) Progressive supranuclear palsy. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Urban & Schwarzenberg, Baltimore, pp 121–130.Google Scholar
- Ishino H, Ikeda H, Otsuki S (1975) Contribution to clinical pathology of progressive supranuclear palsy (subcortical argyrophilic dystrophy). On the distribution of neurofibrillary tangles in the basal ganglia and brain-stem and its clinical significance. J Neurol Sci 24: 471–481.PubMedCrossRefGoogle Scholar
- Jellinger K, Riederer P, Tomonaga M (1980) Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm [Suppl] 16: 111–128.Google Scholar
- Palacios JM, Landwehrmeyer B, Mengod G (1993) Brain dopamine receptors: characterization, distribution and alteration in disease. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders, 2nd edn. Williams & Wilkins, Baltimore, pp 35–54.Google Scholar
- Probst A, Langui D, Lautenschlager C, Ulrich J, Brion JP, Anderton BH (1988) Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer’s disease. Acta Neuropathol 77: 61–68.PubMedCrossRefGoogle Scholar